首页 | 本学科首页   官方微博 | 高级检索  
检索        

血清CEA、SCC、CYFRA21—1、ProGRP联合检测在肺癌诊断中的价值
引用本文:潘俊辉,邱海山.血清CEA、SCC、CYFRA21—1、ProGRP联合检测在肺癌诊断中的价值[J].中华肺部疾病杂志(电子版),2014(4):40-43.
作者姓名:潘俊辉  邱海山
作者单位:广东省惠州市第三人民医院检验科,516002
摘    要:目的 探讨血清癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)、细胞角蛋白19片段(CYFRA21-1)、胃泌素释放肽前体(ProGRP)联合检测在肺癌诊断中的价值。方法 选取2011年3月至2013年8月我院收治的60例已经确诊的肺癌患者,将其作为临床研究对象(实验组),另选取60例良性肺病患者作为对照(对照组),采用酶联免疫分析法检测两组患者的血清CEA、SCC、ProGRP水平,并用电化学发光法测定CYFRA21-1水平,对CEA、SCC、CYFRA21-1和ProGRP 4种肿瘤标志物的阳性率与水平进行比较。结果 实验组血清CEA、SCC、CYFRA21-1和ProGRP 4种肿瘤标志物的阳性率分别为53.3%、21.7%、41.7%、10.0%,对照组血清CEA、SCC、CYFRA21-1和ProGRP 4种肿瘤标志物的阳性率分别为10.0%、15.0%、8.3%、1.7%。实验组血清CEA、SCC、CYFRA21-1和ProGRP的阳性率均明显高于对照组,P〈0.05;实验组血清CEA、SCC、CYFRA21-1和ProGRP 4种肿瘤标志物的水平分别为20.1±2.3、1.0±0.5、8.5±1.6、179.5±37.8,对照组血清CEA、SCC、CYFRA21-1和ProGRP 4种肿瘤标志物的水平分别为3.5±2.1、0.8±0.4、1.1±0.7、4.5±0.6。实验组的血清CEA、SCC、CYFRA21-1和ProGRP水平均明显高于对照组,P〈0.05。结论 采用血清CEA、SCC、CYFRA21-1和ProGRP联合检测可以提高肺癌的诊断效率,对肺癌诊断有很大的临床价值,为患者的疾病治疗争取到了时间,值得在临床大力推广应用。

关 键 词:支气管肺癌  癌胚抗原  鳞状细胞癌抗原  细胞角蛋白19片段  胃泌素释放肽前体  血清标志物  诊断

Application of combination detection of serum CEA,SCC, CYFRA21-1, ProGRP in the diagnosis of lung cancer
Pan Junhui,Qiu Haishan.Application of combination detection of serum CEA,SCC, CYFRA21-1, ProGRP in the diagnosis of lung cancer[J].Chinese Journal of lung Disease(Electronic Edition),2014(4):40-43.
Authors:Pan Junhui  Qiu Haishan
Institution:( Department of clinical laboratory, The Third People's Hospital of Huizhou, Huizhou 516002, China)
Abstract:Objective To discuss and study the application of combined detection of carcino embryonie antigen ( CEA), squamous cell carcinoma antigen ( SCC), cytokeratin 19 fragment ( CYFRA21-1 ), pro-gastrin-releasing peptide (ProGRP) in the diagnosis of lung cancer. Methods A total of 60 lung cancer patients in our hospital from May 2011 to Aug 2013 were selected as the experimental group, and selected another 60 patients with benign pulmonary disease as the control group, the CEA, SCC, ProGRP level of patients were detected by enzyme-linked immunosorbent assay (ELISA), CYFRA21-1 level was detected by electrochemiluminescence, the positive rate of CEA, SCC, CYFRA21-1 and ProGRP other four levels of tumor markers were analyzed. Results The positive rate of the experimental group, serum CEA, SCC, CYFRA21-1 and ProGRP were 53.3%, 21.7%, 41.7%, 10.0% in the control group, the positive rate of serum CEA, SCC, CYFRA21-1 and ProGRP were 10.0%, 15.0%, 8.3%, 1.7%. The positive rate of serum CEA, SCC, CYFRA21-1 and ProGRP were significantly higher than control group, P 〈 0.05 ; four levels of tumor markers in the experimental group, serum CEA, SCC, CYFRA21-1 and ProGRP were 20.1 ±2.3, 1.0 ±0.5, 8.5 ± 1.6, 179.5 ± 37.8, four levels of tumor markers in the control group, serum CEA, SCC, CYFRA21-1 and ProGRP. were 3.5 ±2.1, 0.8 ± 0. 4, 1.1± 0.7, 4.5 ± 0.6. Serum CEA, SCC, CYFRA21-1 levels and ProGRP in expertmental group were significantly higher than control group, P 〈 0.05. Conclusions The diagnostic efficiency of lung cancer can be improved by combined detection of serum CEA, SCC, CYFRA21-1 and ProGRP, it has greatly clinical values in the diagnosis of lung cancer and make more time for disease treatment,which is worthy of being widely promoted in clinic.
Keywords:Bronchogenic carcinoma  Carcino embryonie antigen  Squamous cell carcinoma antigen  Cytokeratin 19 fragment  Pro-gastrin-releasing peptide  Tumor marker  Diagnosis
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号